Form 4: 180 Life Sciences CEO Blair Jordan Boosts Stake and Voting Control Through Equity Awards and Proxy Agreements

180 Life Sciences Corp. CEO Blair Jordan has significantly increased his beneficial ownership and voting control through new equity compensation and irrevocable voting proxies from key shareholders.

Summary

• Blair Jordan, Chief Executive Officer, Director, and 10% Owner of 180 Life Sciences Corp. (ATNF), reported changes in his beneficial ownership.
• Mr. Jordan acquired 179,646 restricted stock shares, subject to time-based vesting (half on December 17, 2025, half on June 17, 2026), issued under the Issuer's 2022 Equity Compensation Plan for services rendered.
• He also acquired 410,000 non-qualified stock options with an exercise price of $0.929, vesting on the same schedule as the restricted stock, issued under the proposed 2025 Option Incentive Plan, which requires stockholder approval.
• Mr. Jordan obtained irrevocable voting proxies for a total of 1,561,166 common shares from three parties: 43,166 shares from Dr. James Woody, 200,000 shares from Dr. Marlene Krauss, and 1,318,000 shares from Elray Resources, Inc.
• These voting agreements allow Mr. Jordan to vote the shares as recommended by the Board of Directors, but he has no dispositive control or pecuniary interest in these shares.
• All acquired securities and voting proxies are indirectly held through Blair Jordan Strategy and Finance Consulting Inc., which Mr. Jordan owns and controls.

Sentiment

Score: 6

Explanation: Slightly positive due to increased CEO alignment and control, but neutral as it's a standard compensation disclosure with potential future dilution and a contingency on stockholder approval for options.

Positives

• The acquisition of restricted stock and stock options aligns the Chief Executive Officer's long-term interests with those of the company and its shareholders.
• The voting agreements consolidate voting power in line with Board recommendations, potentially streamlining corporate governance decisions.
• The equity awards serve as compensation for services rendered and agreed to be rendered by the CEO, indicating continued commitment to the company.

Negatives

• The issuance of new equity awards (restricted stock and options) could lead to future dilution for existing shareholders upon vesting and exercise.
• The non-qualified stock options are contingent on stockholder approval of the 2025 Option Incentive Plan; if not approved, these options will be cancelled.

Risks

• The 410,000 non-qualified stock options are subject to stockholder approval of the 2025 Option Incentive Plan; failure to obtain approval will result in cancellation of these options.
• The vesting of restricted stock and options is contingent on the recipient's continued service to the Issuer, posing a risk if service is terminated.
• While the voting agreements grant voting control, Mr. Jordan has no dispositive control or pecuniary interest in the underlying shares, limiting his direct financial exposure to their performance.

Future Outlook

The future outlook includes the vesting of restricted stock and stock options on December 17, 2025, and June 17, 2026, contingent on continued service. The exercise of the non-qualified stock options is also dependent on obtaining stockholder approval for the 2025 Option Incentive Plan.

Management Comments

• The acquired restricted stock and stock options were issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as Chief Executive Officer.

Industry Context

This SEC Form 4 filing is a standard disclosure of insider trading activity, specifically related to executive compensation and beneficial ownership changes. It reflects a common practice in publicly traded companies to incentivize management through equity awards and, in this case, to consolidate voting power through proxy agreements. While not directly indicative of broader industry trends, it highlights corporate governance mechanisms within the biotechnology or life sciences sector.

Corporate Governance

Related Party Transactions

• The issuance of 179,646 restricted stock shares and 410,000 non-qualified stock options to CEO Blair Jordan constitutes a related party transaction as compensation for services.
• The voting agreements with Dr. James Woody, Dr. Marlene Krauss, and Elray Resources, Inc. are specific arrangements between the CEO (on behalf of the Issuer) and other parties, which could be considered related party dealings depending on their broader relationship with the company.

Stakeholder Impact

• Shareholders: Potential future dilution from the vesting and exercise of new equity awards. Increased management control over voting matters through proxy agreements.
• Employees: The existence of the 2022 Equity Compensation Plan and the proposed 2025 Option Incentive Plan indicates a framework for employee and executive incentives.
• Management: Increased equity stake and voting control for the CEO, aligning his interests with long-term company performance.

Next Steps

• Stockholder approval is required for the 2025 Option Incentive Plan, which will determine the validity of the 410,000 non-qualified stock options.
• The restricted stock and stock options will vest in two tranches: 50% on December 17, 2025, and the remaining 50% on June 17, 2026, subject to continued service.
• The voting agreements with Dr. James Woody, Dr. Marlene Krauss, and Elray Resources, Inc. will remain in effect until their respective expiration dates (February 5, 2026; August 21, 2025; April 28, 2026).

Key Dates

Keywords

SEC Form 4, Insider Ownership, Blair Jordan, 180 Life Sciences Corp., ATNF, CEO Compensation, Restricted Stock, Stock Options, Beneficial Ownership, Voting Agreement, Corporate Governance, Equity Compensation Plan